Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We are the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West and serve patients with all types of cancer from Utah, Idaho, Montana, Nevada, and Wyoming. In 2021, we opened the region’s first proton therapy center. We manage the Utah Population Database, the largest genetic database in the world. More genes for inherited cancers have been discovered at our institution than any place in the world, including genes for melanoma and breast, ovarian, colon, head, and neck cancers.

Connect with us:

Latest from Huntsman Cancer Institute at the University of Utah

Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer

June 09, 2025

Video

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.

Alana Welm, PhD, Named Chair of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah

May 23, 2025

Article

Alana Welm, PhD, is now the chair of the Department of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah.

The ‘Bar Is High’ to Usurp BCG, but Novel Therapies Could Drive Change in Bladder Cancer Management

May 20, 2025

Article

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

First Successful Allogeneic Stem Cell Transplant Using Deceased Donor in Blood Cancer Clinical Trial

May 15, 2025

Article

Huntsman Cancer Institute pioneers a clinical trial using deceased donor stem cells, expanding transplant options for patients with aggressive blood cancers.

Researcher Bruce Edgar Elected to National Academy of Sciences

May 08, 2025

Article

Bruce Edgar, PhD, researcher at Huntsman Cancer Institute, has been elected as a member to the National Academy of Sciences.

Dr Schmidt on FDA-Approved Bladder-Sparing Therapies in BCG-Refractory NMIBC

May 06, 2025

Video

Bogdana Schmidt, MD, MPH, highlights FDA approved bladder-sparing therapies for patients with BCG-refractory non–muscle-invasive bladder cancer.

New Drug Therapy Combination Shows Promise For Advanced Melanoma Patients

March 28, 2025

Article

A federally funded research team is testing a new combination drug therapy that could both treat and prevent melanoma metastasis to the brain.

Anna Parks Receives American Society of Hematology Junior Faculty Scholar Award

February 24, 2025

Article

Anna Parks, MD, Huntsman Cancer Institute investigator, has been awarded the ASH Junior Faculty Scholar Award.

Short-Course Radiation Therapy Effective for Endometrial Cancer Patients

February 12, 2025

Article

Short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

Dr Colman on Outcomes With Eflornithine in Grade 3 Anaplastic Astrocytoma

February 10, 2025

Video

Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.

Dr Schlechter Named Cancer Moonshot Scholar

November 27, 2024

Article

Chelsey Schlechter, MPH, PhD, Huntsman Cancer Institute investigator and assistant professor in the Department of Population Health Sciences at the University of Utah, has been selected as a 2024 Cancer Moonshot Scholar.

Dr Sborov on CAR T-Cell Therapy–Specific Long-Term Treatment Effects in Myeloma

November 11, 2024

Video

Douglas W. Sborov, MD, MS, discusses long-term treatment outcomes for patients with myeloma who received CAR T-cell therapy vs another treatment option.

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients

October 31, 2024

Article

Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

October 28, 2024

Article

Douglas W. Sborov, MD, MS, discusses where ide-cel and cilta-cel each fit into the myeloma treatment paradigm.

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC

October 17, 2024

Article

Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.

Researchers Develop Mechanism that Predicts Severity of Aggressive Form of Breast Cancer

September 13, 2024

Article

Scientists at Huntsman Cancer Institute at the University of Utah, have made a significant breakthrough in predicting the prognosis of triple-negative breast cancer.

Mendoza, Weiss Receive $2.6 Million Grant to Study Biomechanics of Lung Tumors

July 26, 2024

Article

Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth and distribution of tumors.

Landmark Study Shows Elevated Cancer Risk For Women With Endometriosis

July 23, 2024

Article

Women with severe endometriosis are 10 times more likely to get ovarian cancer, compared to women who do not have the disease.

Researchers Honored for Outstanding Contributions to Cancer Care

June 21, 2024

Article

Three Huntsman Cancer Institute researchers have recently been recognized for their work as outstanding faculty members at the University of Utah.

Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC

June 11, 2024

Article

Benjamin L. Maughan, MD, PharmD, highlights ongoing research regarding the role of cytoreductive nephrectomy and targeted therapies in RCC.